Schematic illustration of exposure-driven response models (upper row) and biophase-driven response (bottom row). Schematic illustration of exposure-driven.

Slides:



Advertisements
Similar presentations
Animal Studies and Human Health Consequences Sorell L. Schwartz, Ph.D. Department of Pharmacology Georgetown University Medical Center.
Advertisements

CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Pharmacokinetics of Drug Absorption Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University.
This is Not a Book About …. Author: Illustrator: Class: Date:
1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:
Using extrapolation to support a pediatric investigational plan: an application in liver transplantation development Thomas Dumortier, Martin Fink, Ovidiu.
Applications of Pharmacokinetics
The 3-compartment pharmacokinetic model
INTRODUCTION The oral route of drugs administration is the most important method of administering drugs for systemic effects.
General Toxicology General Considerations in Toxicology Lec
New Frontiers in Cardiology
Hanneke van der Lee, MD, PhD
Gregory L. Kearns, PharmD, FCP 
Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.
Evaluation of models incorporating the base covariates.
Representative radio-HPLC chromatograms for individual pooled methanolic fecal extracts for periods of maximum recovery of radioactivity after dosing of.
Total ion current-EMS chromatograms of SB939 and its metabolites after incubation in liver microsomal fractions for 60 min at a concentration of 50 μM.
Volume 6, Issue 5, Pages e13 (May 2018)
Clinical Nutrition Experimental
Complex Times for Earthquakes, Stocks, and the Brain's Activity
Structure of solid lipid nanoparticles (SLNs).
The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action.
Mechanochemical Symmetry Breaking in Hydra Aggregates
Mechanisms of H2S release from S-aroylthiooximes (SATOs).
Therapeutic Drug Monitoring chapter 1 part 1
Cytotoxic activities of polymer micelles containing CFZ in H460 (A) and select micelle formulations in RPMI-8226 (B) cell lines. Cytotoxic activities of.
Cytotoxic effects of PM1 and PM2 empty particle controls and coincubation of CFZ with empty particles tested in H460 (A) and RPMI-8226 (B) cells. Cytotoxic.
Geometric mean concentration-time profiles of (A) racemic BUP, R-BUP, and S-BUP; (B) racemic OHBUP, RR-OHBUP, and SS-OHBUP; (C) racemic ERY, SR-ERYHBUP,
The additive model assumes unspecific effects of equal size in both the placebo and drug arm or groups of studies or experiments. The additive model assumes.
Introduction to Pharmacology
By Amany Helmy Hasanin Assistant Professor of Clinical Pharmacology
Hannah C. Slater, Lucy C. Okell, Azra C. Ghani  Trends in Parasitology 
Project #1: Drug Kinetics in Genetically Modified Mice
Microbial contribution to drug metabolism.
Volume 27, Issue 9, Pages (May 2017)
(A) Illustration depicting two types of pharmacokinetic instability of an ADC. Conjugating an antibody with drug can accelerate its clearance (green versus.
Introduction to Pharmacology
Chronic effect of 28-day oral administration of vehicle (n = 6–10/group) or aprocitentan 1, 10, and 100 mg/kg per day (n = 6–9/group) on mean arterial.
Effect of 11-day oral administration of vehicle (n = 4) or 6-day oral administration of enalapril 10 mg/kg per day (n = 19), followed by 5-day oral administration.
Three drug delivery strategies for crossing the blood-brain barrier.
Dan-dan Tian1, 2 et al. Acta Pharmacol Sin 2015; 36: 627–643;
F. Estelle R. Simons, MD, FRCPCa, Xiaochen Gu, PhDb, Keith J
Effects of gemfibrozil on the exposure (area under the plasma drug concentration-time curve) to different CYP2C8 substrate drugs. Effects of gemfibrozil.
(A) Plasma renin activity in Wistar rats, SHRs, and DOCA-salt rats, n = 8 to 9/group; data are presented as mean ± S.E.M. Dose-response relationship on.
Schematic illustration of the interaction between CYP2C8 and its glucuronide substrates. Schematic illustration of the interaction between CYP2C8 and its.
Results of thermogravimetric measurements of peptide ghrelin antagonist (GhA) and loaded into PSi microparticles. Results of thermogravimetric measurements.
Drug levels during the course of a dosing interval.
Observed (symbols) and predicted (solid lines, eq
Typical response-time courses obtained after different doses and routes of administration (3 and 10 µg i.v., and 10, 50, and 100 µg s.c.). Typical response-time.
Dose-normalized plasma concentration-time curves of a mAb following subcutaneous (SC) and intravenous (IV) administration to cynomolgus monkeys (mean ±
Fraction of dose (mean, n = 3–4) recovered in peripheral lymph following subcutaneous administration to sheep for a series of small molecular compounds.
Stereoimage of three independent docking simulations of the interaction between clopidogrel acyl 1-β-d-glucuronide and the active site of CYP2C8. Stereoimage.
Damage-associated molecular pattern (DAMP)-induced activation of Toll-like receptors (TLRs). Damage-associated molecular pattern (DAMP)-induced activation.
Schematic diagram illustrating a theoretical model of amygdala modulation of memory and synaptic plasticity in the hippocampus. Schematic diagram illustrating.
Fig. 2 Configuration and composition of urban green space.
(Left) Observed (symbols) and model-predicted (lines) response (tail flick) vs. time of drug X after different doses given by the intravenous (red) and.
Unbound drug concentrations in plasma (dotted) and brain ISF (solid, calculated from recovery and dialysate concentration) following repeated subcutaneous.
(Top) Observed (symbols) and model-predicted (lines) response-time data for latanoprost at the 0.1, 1.0, and 10 µg dose levels in the cat eye. (Top) Observed.
A: Pharmacokinetic (plasma insulin concentration) response to administration of an oral insulin formulation (uninterrupted line) and subcutaneous regular.
Activation and desensitization of the α7 nAChRs.
The effect of a change in the expression level of the receptor and the binding affinity on the subcutaneous bioavailability of mAbs. The effect of a change.
Neighbor joining tree showing relationships between the human cannabinoid CB1 and CB2 receptors and other human rhodopsin α-group type G protein-coupled.
Average trastuzumab serum concentrations in female minipigs following single subcutaneous administration of trastuzumab in formulations without and with.
Allometric relationship between the lymph flow in the thoracic duct and species body weight. Allometric relationship between the lymph flow in the thoracic.
Dose adjustments in patients with CKD are based on the change in the concentration-time profile for the drug of interest. Dose adjustments in patients.
Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose.
(Left) Observed (symbols) and predicted (lines) response (bacterial count, CFU) vs. time after administration of 1.5, 2, 4, and 6 µg of a new antibiotic.
Pharmacodynamic and pharmacokinetic evaluation of EXE-RM-LNC in a high-fat diet (HFD)-induced obese/diabetic mouse model following acute treatment. Pharmacodynamic.
Presentation transcript:

Schematic illustration of exposure-driven response models (upper row) and biophase-driven response (bottom row). Schematic illustration of exposure-driven response models (upper row) and biophase-driven response (bottom row). The plasma concentration is typically the (proxy) driver of the pharmacological model in an exposure (C)–driven model, in contrast to the DRT model in which a biophase compartment model serves as a surrogate for drug exposure. In DRT analyses, information about dose, route, and rate are pivotal for a stringent analysis. The structure of the hypothetical biophase model is assumed to be extracted from the time course(s) of biologic response-time course as such. The underlying assumption about pharmacological response-time data is that some kind of kinetic information is embedded into them, which then may be approximated by the biophase model. In turn, this represents the potential time course (shape) of the total amount of drug in the body that is expected to “drive” the measured pharmacological response. The gray shaded areas are inferred from experimental concentration-time data (upper row) or dosing information (bottom row) coupled to response-time courses. The response-time courses in the DRT analysis provide the extra “kinetic” information to the model that concentration-driven pharmacodynamic models do not need. PO, per oral; SC, subcutaneous. Johan Gabrielsson et al. Pharmacol Rev 2019;71:89-122 Copyright © 2018 by The Author(s)‏